Post hoc analysis compares brolucizumab and aflibercept for diabetic macular edema
A New Eye Injection Works Even If You've Had Treatment Before
A post hoc analysis of a randomized trial in 517 participants with diabetic macular edema compared intravitreal brolucizumab to aflibercept …
People with diabetic eye disease who have already tried other injections may still get meaningful vision improvement from brolucizumab.
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea.
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults.
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.